RIBOZYME AND OMICS
Rznomics announced on the 9th that it has applied to
the U.S. Food and Drug Administration (FDA) for a phase 1/2a clinical trial of
the hepatocellular cancer therapy "RZ-001".
It
is an extension of the domestic clinical trial that was approved by the
Ministry of Food and Drug Safety in June and is being submitted for the
originally planned multinational clinical trial.
Based
on RNA trans-splicing ribozyme, Rznomics is developing a technology that
removes target RNA and simultaneously expresses the desired gene.
RZ-001
is a mechanism that targets the telomerase (hTER) RNA that is specifically
expressed by cancer cells by transferring ribonucleic acid substitution enzymes
through the adenovirus vector and expresses genes that induce anticancer
action.
Rznomics
is also pushing to expand indications to other cancer species, and especially plans
to perform clinical trials on malignant glioblastoma within this year.
In
addition to the anticancer drug pipeline, it is developing therapy in
various fields using platform technologies such as Alzheimer's therapies,
hereditary retinopathy, and Rett’s syndrome.
Genetic
retinal pigmentosa was registered with the Korean Intellectual Property Office
in May, followed by a notification of the registration decision from the U.S. Patent
Office in August to prove its technological progress, the company added.
Seong-wook,
Lee, CEO of Rznomics, said, "The pipelines under development will be
launched sequentially at home and abroad, and we will do our best to provide
patients with new therapy opportunities."